CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
Marks A, Bindra R. CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT. Neuro-Oncology Advances 2021, 3: iv1-iv1. PMCID: PMC8453774, DOI: 10.1093/noajnl/vdab112.002.Peer-Reviewed Original ResearchAdult Brain Tumor ConsortiumAYA populationAYA patientsClinical trialsIDH1/2 mutationsPatients ages 13Years of ageInternational clinical trialsYoung adult populationTemozolomide chemotherapyInitial dosingLack of enrollmentGrade IPsychosocial assessmentPARP inhibitor sensitivityUnique cohortDisease processMost trialsGlioma populationInternational trialTrial developmentAdult populationSpecific trialsPatientsTrials